Crossmark Global Holdings, Inc. Incyte Corp Transaction History

Crossmark Global Holdings, Inc.

$5.5 Billion
Q1 2025

A detailed history of Crossmark Global Holdings, Inc. transactions in Incyte Corp stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 49,850 shares of INCY stock, worth $3.49 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

49,850

Previous 49,978 0.26%

Holding current value

$3.49 Million

Previous $3.45 Million 12.57%

% of portfolio

0.05%

Previous 0.06%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 29, 2025	SELL	$60.0 - $75.26 $7,680 - $9,633	-128 Reduced 0.26%	49,850 $3.02 Million
Q4 2024 Jan 16, 2025	BUY	$65.08 - $83.38 $1.62 Million - $2.08 Million	24,899 Added 99.28%	49,978 $3.45 Million
Q3 2024 Nov 04, 2024	BUY	$57.33 - $68.61 $15,823 - $18,936	276 Added 1.11%	25,079 $1.66 Million
Q2 2024 Jul 29, 2024	SELL	$51.18 - $63.75 $162,547 - $202,470	-3,176 Reduced 11.35%	24,803 $1.5 Million
Q1 2024 May 13, 2024	SELL	$56.55 - $66.59 $260,978 - $307,312	-4,615 Reduced 14.16%	27,979 $1.59 Million
Q4 2023 Feb 13, 2024	SELL	$52.16 - $64.19 $50,125 - $61,686	-961 Reduced 2.86%	32,594 $2.05 Million
Q3 2023 Nov 08, 2023	BUY	$57.77 - $65.93 $483,303 - $551,570	8,366 Added 33.21%	33,555 $1.92 Million
Q2 2023 Jul 31, 2023	SELL	$60.95 - $75.51 $1.16 Million - $1.44 Million	-19,072 Reduced 43.09%	25,189 $1.59 Million
Q1 2023 May 12, 2023	BUY	$70.23 - $86.01 $1.27 Million - $1.56 Million	18,117 Added 69.3%	44,261 $3.2 Million
Q4 2022 Jan 19, 2023	SELL	$67.18 - $84.11 $85,654 - $107,240	-1,275 Reduced 4.65%	26,144 $2.1 Million
Q3 2022 Nov 01, 2022	BUY	$66.18 - $82.86 $430,699 - $539,252	6,508 Added 31.12%	27,419 $1.83 Million
Q2 2022 Jul 29, 2022	BUY	$66.18 - $83.18 $99,270 - $124,770	1,500 Added 7.73%	20,911 $1.59 Million
Q1 2022 May 11, 2022	BUY	$66.02 - $79.71 $52,155 - $62,970	790 Added 4.24%	19,411 $1.54 Million
Q4 2021 Jan 10, 2022	SELL	$63.34 - $74.11 $1,266 - $1,482	-20 Reduced 0.11%	18,621 $1.37 Million
Q3 2021 Oct 21, 2021	BUY	$68.67 - $84.02 $1.28 Million - $1.57 Million	18,641 New	18,641 $1.28 Million
Q3 2021 Oct 13, 2021	SELL	$68.67 - $84.02 $1.24 Million - $1.51 Million	-18,001 Closed	0 $0
Q2 2021 Jul 21, 2021	BUY	$79.87 - $87.53 $27,954 - $30,635	350 Added 1.98%	18,001 $1.51 Million
Q1 2021 Apr 15, 2021	SELL	$76.02 - $100.5 $85,902 - $113,565	-1,130 Reduced 6.02%	17,651 $1.43 Million
Q4 2020 Jan 14, 2021	SELL	$80.74 - $97.7 $777,526 - $940,851	-9,630 Reduced 33.9%	18,781 $1.63 Million
Q3 2020 Oct 08, 2020	BUY	$85.07 - $109.69 $59,889 - $77,221	704 Added 2.54%	28,411 $2.55 Million
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $143,909 - $211,324	-1,940 Reduced 6.54%	27,707 $2.88 Million
Q1 2020 Apr 28, 2020	BUY	$63.18 - $85.97 $58,820 - $80,038	931 Added 3.24%	29,647 $0
Q4 2019 Feb 06, 2020	BUY	$73.04 - $95.72 $1.11 Million - $1.46 Million	15,249 Added 113.23%	28,716 $2.51 Million
Q3 2019 Oct 09, 2019	SELL	$72.82 - $86.52 $29,564 - $35,127	-406 Reduced 2.93%	13,467 $1 Million
Q2 2019 Jul 09, 2019	SELL	$73.52 - $88.7 $588 - $709	-8 Reduced 0.06%	13,873 $1.18 Million
Q1 2019 May 02, 2019	SELL	$63.56 - $88.17 $5,593 - $7,758	-88 Reduced 0.63%	13,881 $1.19 Million
Q4 2018 Jan 31, 2019	SELL	$58.5 - $69.94 $322,335 - $385,369	-5,510 Reduced 28.29%	13,969 $888,000
Q3 2018 Nov 08, 2018	SELL	$61.75 - $74.23 $27,293 - $32,809	-442 Reduced 2.22%	19,479 $1.35 Million
Q2 2018 Jul 31, 2018	SELL	$60.85 - $83.98 $28,599 - $39,470	-470 Reduced 2.3%	19,921 $1.34 Million
Q1 2018 Apr 16, 2018	SELL	$83.06 - $100.98 $65,783 - $79,976	-792 Reduced 3.74%	20,391 $1.7 Million
Q4 2017 Feb 05, 2018	BUY	$93.56 - $116.6 $26,477 - $32,997	283 Added 1.35%	21,183 $2.01 Million
Q3 2016 Oct 25, 2017	BUY	N/A	20,900	20,900 $2.44 Million

Others Institutions Holding INCY

# of Institutions

695

Shares Held

194M

Call Options Held

564K

Put Options Held

331K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account

Crossmark Global Holdings, Inc. Incyte Corp Transaction History